Traumatic brain injury (TBI) results in cognitive impairment, which can be long-lasting after moderate to severe TBI. Currently, there are no FDA-approved therapeutics to treat the devastating consequences of TBI and…(Read More)
Dopaminergic neuronal cell loss in the substantia nigra is responsible for the motor symptoms that are the clinical hallmark of Parkinson’s disease (PD). As of yet there are no treatments that slow or prevent the degeneration of…(Read More)
Mitochondrial dysfunction is thought to be involved in the pathogenesis of MS and here we tested if brain penetrant mitochondrial uncouplers, DNP (MP101) and a novel prodrug of DNP (MP201), have the pharmacology to suppress demyelination and axonal loss in two independent models of MS by modulating the entire…(Read More)
By Erica Slaughter Huntington disease (HD), a genetically dominant trinucleotide repeat disorder resulting from cytosine-adenine-guanine (CAG) repeats within the huntingtin (HTT) gene, has a near-full pene- trance and onset of symptomatology and neuronal loss typically by the third decade of life. A neuropathological hallmark of HD is cortical atrophy, as indicated in…(Read More)
In the sanctity of pure drug discovery, objective reasoning can become clouded when pursuing ideas that appear unorthodox, but are spot on physiologically. To put this into historical perspective, it was an unorthodox idea in the 1950’s to suggest that warfarin, a rat poison, could be repositioned into a breakthrough drug in humans…(Read More)
Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced that it was awarded Orphan Drug Designation by FDA for its mitochondrial targeted compound, MP-101 for treating Huntington’s Disease. This important allowance, along with the Company’s open IND will help secure the path forward for the continued clinical development of MP101 in Huntington…(Read More)
Disease Modifying Therapies for Neurodegenerative Diseases…(Read More)
Blue Bell, Pennsylvania (BUSINESS WIRE) — Mitochon Pharmaceuticals today announced that it was notified by the US Patent and Trade Mark Office of allowance on its first patent, US 15/002,531 “INDUCED EXPRESSION OF BRAIN DERIVED NEUROTROPHIC FACTOR (BDNF) FOR TREATMENT OF NEUROMUSCULAR, NEURODEGENERATIVE, AUTOIMMUNE, DEVELOPMENTAL AND/OR METABOLIC DISEASE”. This patent allowance will help…(Read More)
Blue Bell, Pennsylvania (BUSINESS WIRE)–Mitochon Pharmaceuticals today announced that it was awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to help develop its mitochondrial targeted compounds for treating Parkinson’s disease. The funding will go to pivotal animal studies to assess the benefits of Mitochon’s compounds in…(Read More)
Optic neuritis is an inflammatory demyelinating disease of the optic nerve often associated with multiple sclerosis (MS) [1]. Optic neuritis may lead to complete or partial loss of vision in one or both eyes [2]. In 15%–20% of people who eventually develop MS, optic neuritis is their first symptom [3]. Current therapies used for…(Read More)